AIM: To evaluate the safety and efficacy of intracameral moxifloxacin in preventing endophthalmitis after cataract surgery.

METHODS:Sixty-five eyes of 65 patients underwent cataract surgery between January and June 2012. Some patients received intracameral moxifloxacin at the end of surgery, while others did not(controls). Pre- and postperative logarithm of the minimum angle of resolution(logMAR)best corrected visual acuity(BCVA), intraocular pressure(IOP), corneal edema, and anterior chamber(AC)status were examined.

RESULTS: Thirty-three patients(19 males, 14 females); average age, 64.81±11.61y(range: 41-82y)received moxifloxacin and 32 patients(15 males, 17 females); average age, 65.43±11.10y(range: 42-81y)did not. The differences in patient age(P=0.827)and sex(P=0.396)were insignificant. Preoperative BCVA was approximately 20/130 in both groups. After surgery, moxifloxacin and control patients had a BCVA of 20/25 and 20/23, respectively(P=0.160). Preoperative IOP was 14.93±2.77mmHg(range: 11-21mmHg)in moxifloxacin patients and 15.06±2.42mm Hg(range: 12-21mmHg)in controls(P=0.850). After surgery, IOP was not statistically different between two groups(moxifloxacin: 14.06±2.31(range: 10-19mmHg), controls: 14.03±2.36mmHg(range: 10-19mmHg), P=0.960). Slight differences in corneal edema(P=0.623)and anterior chamber cell(P=0.726)incidences between two groups were not statistically significant.

CONCLUSION: Intracameral moxifloxacin is safe and effective in preventing endophtalmitis after cataract surgery.